{"id":"methylphenidate-hcl-erct","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Insomnia"},{"rate":"10-20","effect":"Decreased appetite"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Nervousness/anxiety"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Weight loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate blocks the dopamine transporter (DAT) and norepinephrine transporter (NET), preventing the reuptake of these neurotransmitters from the synaptic cleft back into presynaptic neurons. The extended-release controlled-release technology (ERCT) formulation provides sustained drug delivery over an extended period, maintaining therapeutic levels throughout the day. This mechanism enhances attention, focus, and impulse control in patients with attention deficit hyperactivity disorder.","oneSentence":"Methylphenidate HCl ERCT is an extended-release formulation that inhibits the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:35.690Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT03546400","phase":"PHASE4","title":"Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2018-09-25","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":""},{"nctId":"NCT03536390","phase":"PHASE4","title":"A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2018-09-19","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT03580005","phase":"PHASE4","title":"A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2018-10-31","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"methylphenidate HCl ERCT","genericName":"methylphenidate HCl ERCT","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylphenidate HCl ERCT is an extended-release formulation that inhibits the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, Narcolepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}